Stocks · News reference
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 3.33 percent decrease over losses of $(0.30) per share
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
Read original at benzingaInsight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Read original at benzingaNeedham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $9 price target.
Read original at benzingaInsight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola
Read original at benzinga